- Home
- CISO vs GDTC Comparison
CISO vs GDTC Comparison
Compare CISO & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CISO
- GDTC
- Stock Information
- Founded
- CISO 2015
- GDTC 2018
- Country
- CISO United States
- GDTC Singapore
- Employees
- CISO N/A
- GDTC N/A
- Industry
- CISO Computer Software: Prepackaged Software
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- CISO Technology
- GDTC Health Care
- Exchange
- CISO Nasdaq
- GDTC Nasdaq
- Market Cap
- CISO 12.4M
- GDTC 29.4M
- IPO Year
- CISO N/A
- GDTC 2023
- Fundamental
- Price
- CISO $1.09
- GDTC $2.67
- Analyst Decision
- CISO
- GDTC Buy
- Analyst Count
- CISO 0
- GDTC 1
- Target Price
- CISO N/A
- GDTC $5.00
- AVG Volume (30 Days)
- CISO 401.5K
- GDTC 12.2K
- Earning Date
- CISO 04-15-2025
- GDTC 01-01-0001
- Dividend Yield
- CISO N/A
- GDTC N/A
- EPS Growth
- CISO N/A
- GDTC N/A
- EPS
- CISO N/A
- GDTC N/A
- Revenue
- CISO $54,633,909.00
- GDTC $330,254.00
- Revenue This Year
- CISO $78.76
- GDTC $14.71
- Revenue Next Year
- CISO N/A
- GDTC N/A
- P/E Ratio
- CISO N/A
- GDTC N/A
- Revenue Growth
- CISO 34.87
- GDTC N/A
- 52 Week Low
- CISO $0.26
- GDTC $1.20
- 52 Week High
- CISO $3.84
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- CISO 50.35
- GDTC 48.99
- Support Level
- CISO $0.96
- GDTC $2.42
- Resistance Level
- CISO $1.10
- GDTC $2.80
- Average True Range (ATR)
- CISO 0.14
- GDTC 0.19
- MACD
- CISO 0.01
- GDTC -0.02
- Stochastic Oscillator
- CISO 54.15
- GDTC 64.10
About CISO CISO Global Inc.
CISO Global Inc provides cybersecurity services. The services are used to protect client's data, financial information, intellectual property, and business reputation. The services include penetration testing, security remediation, compliance auditing, vulnerability assessment, and others. Geographically, the company operates in U.S., Chile and All other countries. The maximum revenue is generated from U.S.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.